Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline
Methodological detailsGRADE approach, linked living systematic review and network meta-analysis, BMJ Rapid Recommendations, Evidence updated to 31 July 2024, First version of the living guideline, International panel incl. two patient partners, clinicians and methodologists
- GRADE approach
- Linked living systematic review and network meta-analysis
- BMJ Rapid Recommendations
- Evidence updated to 31 July 2024
- First version of the living guideline
- International panel incl. two patient partners, clinicians and methodologists
Recommendations
As issued by the authors
- weak recommendation against
Lower risk (≤3 cardiovascular risk factors without established cardiovascular disease (CVD) or chronic kidney disease (CKD)): against SGLT-2 inhibitors or GLP-1 RA
- weak recommendation in favour
Moderate risk (>3 cardiovascular risk factors without established CVD or CKD; or established CVD and/or CKD at lower risk of complications): in favour of SGLT-2 inhibitors or GLP-1 RA
- weak recommendation against
Moderate risk: against finerenone in adults with CKD
- strong recommendation in favour
Higher risk (established CVD and/or CKD at higher risk of complications, or established HF): in favour of SGLT-2 inhibitors or GLP-1 RA
- weak recommendation in favour
Higher risk: in favour of finerenone in adults with CKD
- weak recommendation in favour
Across risk strata: in favour of tirzepatide in adults with obesity
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →